Perrigo (PRGO) Asset Writedowns and Impairment (2015 - 2026)
Perrigo (PRGO) posted quarterly Asset Writedowns and Impairment of $330.8 million for Q1 2026, up 10570.97% year-over-year from N/an in Q1 2025, and down 75.65% quarter-over-quarter from $1.4 billion in Q4 2025.
Perrigo (PRGO) Asset Writedowns and Impairment (2015 - 2026) Analysis & Trends
Perrigo (PRGO) has reported Asset Writedowns and Impairment for 11 consecutive years, with $330.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Asset Writedowns and Impairment rose 10570.97% year-over-year to $330.8 million; the TTM figure through Mar 2026 stood at $1.7 billion (up 1183.83% YoY), while the FY2025 annual figure was $1.4 billion, up 1433.3% from the prior year.
- Asset Writedowns and Impairment retreated to $330.8 million in Q1 2026 per PRGO's latest filing, from $1.4 billion in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $1.4 billion in Q4 2025 and bottomed at $1.5 million in Q2 2025.
- Historically, Asset Writedowns and Impairment has averaged $234.1 million across 4 years, with a median of $36.4 million in 2024.
- Annual changes were most pronounced in 2025 — Asset Writedowns and Impairment tumbled 95.6% — and 2026, when it jumped 10570.97%.
- Perrigo's Asset Writedowns and Impairment stood at $90.0 million in 2023, then plunged by 57.11% to $38.6 million in 2024, then surged by 3419.43% to $1.4 billion in 2025, then slumped by 75.65% to $330.8 million in 2026.
- Business Quant data shows PRGO's Asset Writedowns and Impairment at $330.8 million in Q1 2026, $1.4 billion in Q4 2025, and $1.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | Perrigo | 1.94 Bn | 1.54 Bn | 313.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 27, 2026 | 1.00 Mn |
| Jun 27, 2026 | 1.00 Mn |
| Mar 28, 2026 | 330.80 Mn |
| Mar 28, 2026 | 330.80 Mn |
| Dec 31, 2025 | 1.36 Bn |
| Dec 31, 2025 | 1.36 Bn |
| Jun 28, 2025 | 1.50 Mn |
| Jun 28, 2025 | 1.50 Mn |
| Mar 29, 2025 | 3.10 Mn |
| Mar 29, 2025 | 3.10 Mn |
| Dec 31, 2024 | 38.60 Mn |
| Dec 31, 2024 | 38.60 Mn |
| Sep 28, 2024 | 16.20 Mn |
| Sep 28, 2024 | 16.20 Mn |
| Jun 29, 2024 | 34.10 Mn |
| Jun 29, 2024 | 34.10 Mn |
| Dec 31, 2023 | 90.00 Mn |
| Dec 31, 2023 | 90.00 Mn |
| Dec 31, 2021 | 11.00 Mn |
| Dec 31, 2021 | 11.00 Mn |